ES2741476T3 - Método para el tratamiento o reducción de PFE - Google Patents

Método para el tratamiento o reducción de PFE Download PDF

Info

Publication number
ES2741476T3
ES2741476T3 ES12842537T ES12842537T ES2741476T3 ES 2741476 T3 ES2741476 T3 ES 2741476T3 ES 12842537 T ES12842537 T ES 12842537T ES 12842537 T ES12842537 T ES 12842537T ES 2741476 T3 ES2741476 T3 ES 2741476T3
Authority
ES
Spain
Prior art keywords
collagenase
injection
pfe
administered
area
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12842537T
Other languages
English (en)
Spanish (es)
Inventor
Susan G Hart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Endo Global Ventures
Original Assignee
Endo Global Ventures
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Endo Global Ventures filed Critical Endo Global Ventures
Application granted granted Critical
Publication of ES2741476T3 publication Critical patent/ES2741476T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Birds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES12842537T 2011-10-21 2012-10-19 Método para el tratamiento o reducción de PFE Active ES2741476T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161549863P 2011-10-21 2011-10-21
PCT/US2012/061063 WO2013059619A1 (en) 2011-10-21 2012-10-19 Method of treating or reducing efp

Publications (1)

Publication Number Publication Date
ES2741476T3 true ES2741476T3 (es) 2020-02-11

Family

ID=48141393

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12842537T Active ES2741476T3 (es) 2011-10-21 2012-10-19 Método para el tratamiento o reducción de PFE
ES19172643T Active ES2953560T3 (es) 2011-10-21 2012-10-19 Procedimiento para el tratamiento o reducción de paniculopatía fibrosclerótica edematosa

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES19172643T Active ES2953560T3 (es) 2011-10-21 2012-10-19 Procedimiento para el tratamiento o reducción de paniculopatía fibrosclerótica edematosa

Country Status (14)

Country Link
US (2) US20140335072A1 (enExample)
EP (2) EP2768523B1 (enExample)
JP (5) JP2014530873A (enExample)
AU (6) AU2012325941A1 (enExample)
BR (1) BR112014009785B1 (enExample)
CA (1) CA2852942C (enExample)
DK (2) DK3581199T3 (enExample)
ES (2) ES2741476T3 (enExample)
FI (1) FI3581199T3 (enExample)
HU (2) HUE063599T2 (enExample)
MX (2) MX392388B (enExample)
PL (1) PL3581199T3 (enExample)
PT (2) PT3581199T (enExample)
WO (1) WO2013059619A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013208028B2 (en) 2012-01-12 2016-04-28 Auxilium International Holdings, Inc. Clostridium histolyticum enzymes and methods for the use thereof
EP2844276B1 (en) 2012-05-01 2019-10-02 Proteolease Ltd. Methods for extracting a tooth
WO2014144859A1 (en) 2013-03-15 2014-09-18 Biospecifics Technologies Corporation Treatment method and product for uterine fibroids using purified collagenase
CN103751102A (zh) * 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
BR112019018277A2 (pt) * 2017-03-01 2020-06-30 Endo Ventures Limited aparelho e método para avaliar e tratar celulite
KR20250171475A (ko) * 2017-03-28 2025-12-08 엔도 오퍼레이션즈 리미티드 개선된 콜라게나제 생성 방법
WO2020021332A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
MX2021000901A (es) * 2018-07-23 2021-06-18 Revelle Aesthetics Inc Sistema y metodos de tratamiento de celulitis.
ES2989422T3 (es) 2018-07-23 2024-11-26 Revelle Aesthetics Inc Sistema de tratamiento de celulitis
CA3112437A1 (en) * 2018-09-18 2020-03-26 Endo Global Aesthetics Limited Compositions and methods for treating cellulite
KR20210113271A (ko) * 2019-01-06 2021-09-15 엔도 글로벌 에스테틱스 리미티드 콜라게나제 제형 및 이의 제조 방법
CA3153485A1 (en) 2019-09-06 2021-03-11 Revelle Aesthetics, Inc. Cellulite treatment system and methods
US11872267B2 (en) 2019-10-15 2024-01-16 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
EP3861948A1 (en) * 2020-02-10 2021-08-11 Daniel A. Del Vecchio Cellulite eradication methods

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4645668A (en) 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US6958150B2 (en) * 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
ES2372499T3 (es) * 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Uso de un detergente para la eliminación no quirúrgica de grasa.
US20070224184A1 (en) * 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
WO2007100590A2 (en) * 2006-02-22 2007-09-07 Auxilium Pharmaceuticals, Inc. Methods for treating cellulite
US8617543B2 (en) * 2007-02-14 2013-12-31 Yolare Pharmaceuticals, LLC Modified mutant collagenase and its use in fat melting and in scar reduction

Also Published As

Publication number Publication date
AU2022202987B2 (en) 2025-03-20
AU2020200763B2 (en) 2022-05-26
NZ722722A (en) 2019-05-31
EP3581199A1 (en) 2019-12-18
JP2022123073A (ja) 2022-08-23
HUE044650T2 (hu) 2019-11-28
HUE063599T2 (hu) 2024-01-28
DK3581199T3 (da) 2023-09-04
US20140335072A1 (en) 2014-11-13
FI3581199T3 (fi) 2023-08-18
CA2852942C (en) 2023-01-10
AU2012325941A1 (en) 2014-05-15
BR112014009785A8 (pt) 2020-02-27
JP2020158521A (ja) 2020-10-01
BR112014009785B1 (pt) 2020-06-30
PL3581199T3 (pl) 2023-09-11
NZ769098A (en) 2022-03-25
DK2768523T3 (da) 2019-07-22
JP2024123126A (ja) 2024-09-10
US20240216485A1 (en) 2024-07-04
AU2020200763A1 (en) 2020-02-20
AU2016202026A1 (en) 2016-04-21
NZ624057A (en) 2016-08-26
MX392388B (es) 2025-03-24
EP2768523B1 (en) 2019-05-22
CA2852942A1 (en) 2013-04-25
AU2022202987A1 (en) 2022-05-26
WO2013059619A1 (en) 2013-04-25
AU2017248451A1 (en) 2017-11-02
NZ737403A (en) 2020-05-29
BR112014009785A2 (pt) 2017-04-25
JP2018027968A (ja) 2018-02-22
EP2768523A1 (en) 2014-08-27
MX2014004792A (es) 2015-08-14
EP3581199B1 (en) 2023-05-31
PT2768523T (pt) 2019-08-29
ES2953560T3 (es) 2023-11-14
JP2014530873A (ja) 2014-11-20
AU2017248451B2 (en) 2019-11-14
MX2019007779A (es) 2019-09-04
HK1201439A1 (en) 2015-09-04
AU2025204462A1 (en) 2025-07-03
PT3581199T (pt) 2023-08-31
EP2768523A4 (en) 2015-04-22
NZ759819A (en) 2020-11-27

Similar Documents

Publication Publication Date Title
ES2741476T3 (es) Método para el tratamiento o reducción de PFE
Cavallini et al. The role of hyaluronidase in the treatment of complications from hyaluronic acid dermal fillers
ES2199209T3 (es) Uso de neurotoxinas en medicamentos para trastornos del tiroides.
US12440543B2 (en) Botulinum toxin type a complex, and formulation thereof and usage method therefor
JP2021527134A (ja) 皮膚状態の処置のための組成物
HK40020065A (en) Methods of treatment or reduction of edematous-fibrosclerotic panniculopathy
HK40020065B (en) Methods of treatment or reduction of edematous-fibrosclerotic panniculopathy
NZ624057B2 (en) Method of treating or reducing efp
HK1201439B (en) Method of treating or reducing efp
NZ722722B2 (en) Method of treating or reducing efp
NZ737403B2 (en) Method of treating or reducing efp
NZ769098B2 (en) Method of treating or reducing efp
NZ759819B2 (en) Method of treating or reducing efp
TW202138002A (zh) A型肉毒桿菌毒素複合物、其配製劑和使用方法
VENOMS International Research Journal for Inventions in Pharmaceutical Sciences
Zozulińska et al. Assessment of plasma fibronectin concentration in type 1 diabetic patients